BioVie Announces Phase 2 Trial Assessing NE3107’s Pro-motoric Activity In Parkinson’s Disease Is Fully Enrolled
October 19, 6:04 AM
BioVie Inc., (NASDAQ:BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and
September 28, 3:01 PM
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to $99.90 on Wednesday.
September 28, 9:13 AM
Apple (AAPL) - Shares traded down about 2.5% Tuesday evening following a report the company pulled back its iPhone 14 production ramp up, citing underwhelming demand. Several notable analysts, including Loup
September 9, 8:18 AM
September 7, 10:03 AM
BioVie's (NASDAQ:BIVI) short percent of float has fallen 67.41% since its last report. The company recently reported that it has 54 thousand shares sold short, which is 0.44% of all regular shares that are available for trading.
Top Financial Stories Wednesday, September 07: Musk Cited Putin Worries To Delay Twitter Deal, Apple To Defend Move Of Selling iPhones Without Charger, Deutsche Bank CEO Signals Recession Risks And More..
September 7, 8:17 AM
Wall Street Journal
September 7, 7:08 AM
BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…
BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’
September 7, 6:03 AM
Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05). NE3107 is
September 7, 5:16 AM
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.